Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment

Chih-Jen Yang,1–4 Ming-Ju Tsai,2,4 Jen-Yu Hung,2,3 Ta-Chih Liu,3,5 Shah-Hwa Chou,3,6 Jui-Ying Lee,6 Jui-Sheng Hsu,3,7 Ying-Ming Tsai,1,2,4 Ming-Shyan Huang,2–4 Inn-Wen Chong2,3 1Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, 2Division of Pulmonary and Cri...

Full description

Bibliographic Details
Main Authors: Yang CJ, Tsai MJ, Hung JY, Liu TC, Chou SH, Lee JY, Hsu JS, Tsai YM, Huang MS, Chong IW
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:OncoTargets and Therapy
Subjects:
epidermal growth factor receptor
gefitinib
acquired resistance
pemetrexed
chemotherapy
Online Access:https://www.dovepress.com/pemetrexed-had-significantly-better-clinical-efficacy-in-patients-with-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/pemetrexed-had-significantly-better-clinical-efficacy-in-patients-with-peer-reviewed-article-OTT

Similar Items